Medical Developments International (MDI) has signed a distribution and licensing agreement with Purdue Pharma for Penthrox Inhaler, Canada.
The low-dose methoxyflurane Penthrox is an inhaled, non-narcotic analgesic drug / device combination that provides emergency relief of moderate to severe pain in conscious adult patients suffering with trauma and associated pain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MDI CEO John Sharman said: “This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain.
“Purdue has market leading expertise in pain management products and will invest in providing the educational resources to healthcare practitioners on the appropriate use, benefits, and safety profile of Penthrox.”
Penthrox is approved for marketing in 15 countries including Australia, the UK, Ireland, France and Belgium.
Purdue Pharma president and CEO Dr Craig Landau said: “Subject to regulatory approval by Health Canada, Penthrox will provide Canadian patients and ER Physicians with an important, non-opioid treatment option for medical situations involving acute trauma pain that is moderate to severe in nature.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Penthrox nicely complements, and will provide additional diversification to our existing analgesic product portfolio.”
MDI recently received regulatory approval and the marketing authorisation for the sale of Penthrox in the United Arab Emirates.
